PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY PRODUCT Market segmentation by product Comparison by product Small molecules - Market size and forecast 2018-2023 Biologics - Market size and forecast 2018-2023 Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Development of gene therapy Special designations Increasing popularity of combination therapies PART 12: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors AbbVie Inc. Allergan Plc Johnson & Johnson Services Inc. Novartis AG Pfizer Inc. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global ophthalmology drugs market Exhibit 02: Segments of global ophthalmology drugs market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Product - Market share 2018-2023 (%) Exhibit 18: Comparison by product Exhibit 19: Small molecules - Market size and forecast 2018-2023 ($ millions) Exhibit 20: Some of the generic sponsors for corticosteroids Exhibit 21: Different forms of corticosteroids Exhibit 22: Small molecules - Year-over-year growth 2019-2023 (%) Exhibit 23: Biologics - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Some of the biologics used in uveitis Exhibit 25: Cost of some biologics Exhibit 26: Some of the approved biosimilars Exhibit 27: Biologics - Year-over-year growth 2019-2023 (%) Exhibit 28: Market opportunity by product Exhibit 29: Customer landscape Exhibit 30: Market share by geography 2018-2023 (%) Exhibit 31: Geographic comparison Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 33: North America - Year-over-year growth 2019-2023 (%) Exhibit 34: Top 3 countries in North America Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 36: Europe - Year-over-year growth 2019-2023 (%) Exhibit 37: Top 3 countries in Europe Exhibit 38: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 39: Asia - Year-over-year growth 2019-2023 (%) Exhibit 40: Top 3 countries in Asia Exhibit 41: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 42: ROW - Year-over-year growth 2019-2023 (%) Exhibit 43: Top 3 countries in ROW Exhibit 44: Key leading countries Exhibit 45: Market opportunity Exhibit 46: Prevalence of associated risk factors for uveitis Exhibit 47: Drug development pipeline late stage molecules for uveitis Exhibit 48: Adverse effects associated with available drugs Exhibit 49: Impact of drivers and challenges Exhibit 50: Vendor landscape Exhibit 51: Landscape disruption Exhibit 52: Vendors covered Exhibit 53: Vendor classification Exhibit 54: Market positioning of vendors Exhibit 55: AbbVie Inc. - Vendor overview Exhibit 56: AbbVie Inc. - Business segments Exhibit 57: AbbVie Inc. - Organizational developments Exhibit 58: AbbVie Inc. - Geographic focus Exhibit 59: AbbVie Inc. - Key offerings Exhibit 60: AbbVie Inc. - Key customers Exhibit 61: Allergan Plc - Vendor overview Exhibit 62: Allergan Plc - Business segments Exhibit 63: Allergan Plc - Organizational developments Exhibit 64: Allergan Plc - Geographic focus Exhibit 65: Allergan Plc - Segment focus Exhibit 66: Allergan Plc - Key offerings Exhibit 67: Allergan Plc - Key customers Exhibit 68: Johnson & Johnson Services, Inc. - Vendor overview Exhibit 69: Johnson & Johnson Services, Inc. - Business segments Exhibit 70: Johnson & Johnson Services, Inc. - Organizational developments Exhibit 71: Johnson & Johnson Services, Inc. - Geographic focus Exhibit 72: Johnson & Johnson Services, Inc. - Segment focus Exhibit 73: Johnson & Johnson Services, Inc. - Key offerings Exhibit 74: Johnson & Johnson Services, Inc. - Key customers Exhibit 75: Novartis AG - Vendor overview Exhibit 76: Novartis AG - Business segments Exhibit 77: Novartis AG - Organizational developments Exhibit 78: Novartis AG - Geographic focus Exhibit 79: Novartis AG - Segment focus Exhibit 80: Novartis AG - Key offerings Exhibit 81: Novartis AG - Key customers Exhibit 82: Pfizer Inc. - Vendor overview Exhibit 83: Pfizer Inc. - Business segments Exhibit 84: Pfizer Inc. - Organizational developments Exhibit 85: Pfizer Inc. - Geographic focus Exhibit 86: Pfizer Inc. - Segment focus Exhibit 87: Pfizer Inc. - Key offerings Exhibit 88: Pfizer Inc. - Key customers Exhibit 89: Validation techniques employed for market sizing Exhibit 90: Definition of market positioning of vendors

AbbVie Inc. Allergan Plc Johnson & Johnson Services Inc. Novartis AG Pfizer Inc.